Gilead (GILD) Gets EU Nod for Breast Cancer Drug, Trodelvy
Gilead Sciences, Inc. GILD announced that the European Commission has granted marketing authorization to Trodelvy (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (“TNBC”) who ... [Read]